Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2020-08-10 Regulatory Filings
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel
Regulatory Filings Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The key content states: 'Attached hereto is a report on *Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial...* *CT_COVID19_FINAL_isa.pdf*'. Since the document itself is short (2052 chars) and serves primarily to announce the publication of an attached report (a clinical trial update, which is not explicitly covered by other codes like ER, IR, or LTR), it fits the definition of a Report Publication Announcement (RPA) or, given its regulatory nature and lack of a better fit, a general Regulatory Filing (RNS). Given the structure, which is a formal notification about the release of specific information, RPA is a strong candidate if the attached PDF is the main substance. However, since the content is a specific regulatory announcement about a clinical trial milestone, and it is not a standard financial report (10-K, IR, ER), RNS (Regulatory Filings - general fallback for miscellaneous regulatory announcements) is often used for such specific, non-standard disclosures on TASE/ISA, especially when the primary action is the filing itself rather than the content of the attached report being the focus of the classification system (which prioritizes financial reports). Given the explicit mention of 'Immediate Report' and the attachment of a specific PDF, RNS is the most appropriate general regulatory category for this type of specific, non-financial disclosure filing.
2020-08-10 English
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed by a Foreign Private Issuer (Kamada Ltd.) with the SEC. Form 6-K is used to report material information that a foreign company is required to disclose to its home country's regulators or stock exchange. The content attached as Exhibit 99.1 is a press release announcing the upcoming release of Q2 2020 financial results and a conference call to discuss them. This structure—a Form 6-K filing that primarily serves to submit an earnings announcement press release—is a common regulatory filing mechanism for foreign issuers. Since the document itself is the SEC filing (Form 6-K) containing the announcement, and not the full earnings release (ER) or the call transcript (CT), it falls best under the general category for miscellaneous regulatory filings that don't fit the specific report types (like 10-K, IR, ER). Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a standard SEC filing form used for timely disclosure.
2020-08-05 English
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
Report Publication Announcement Classification · 1% confidence The document text explicitly states: 'Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020'. This indicates an announcement about the upcoming release of quarterly financial results and a related conference call, rather than the full results document itself (which would be an IR or ER). Since the document is short (1954 chars) and serves primarily to announce the timing of the results release and call, it fits the definition of a Report Publication Announcement (RPA). It is not a full Earnings Release (ER) as it only announces the date, not the figures.
2020-08-05 English
Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed with the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION." Form 6-K is the standard filing used by Foreign Private Issuers to report material information that is made public in their home country or exchange. The content is a press release announcing the availability of a COVID-19 therapy and updates on clinical trials. This type of material event disclosure, filed on Form 6-K, is generally classified as a general Regulatory Filing (RNS) or, if the content were a specific financial report, it might map elsewhere. However, since the core document is the SEC filing wrapper (Form 6-K) containing a press release about business operations and clinical progress, and there is no specific category for Form 6-K, the most appropriate classification is the general regulatory announcement category, RNS, as it is a mandatory disclosure to the SEC. Reviewing the definitions: - It is not an Annual Report (10-K). - It is not a standalone Audit Report (AR). - It is not a specific financial release like ER or IR. - It is a regulatory filing containing material news, making RNS the best fit among the provided options for a non-standard SEC form disclosure.
2020-06-17 English
Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel
Report Publication Announcement Classification · 1% confidence The document is very short (2029 characters) and explicitly states, 'Attached hereto is a report on*Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel* *ea123125-6k_kamadaltdEDGAR2_Bannerless_isa.pdf'. This structure—a brief announcement referencing an attached or linked primary document—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is not the full report itself (like 10-K or IR), but rather the notice that the report is available.
2020-06-17 English
Kamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress
Earnings Release Classification · 1% confidence The document is explicitly identified as a "FORM 6-K Report of Foreign Private Issuer" filed with the SEC for the month of May 2020. The content attached (Exhibit 99.1 and 99.2) is a press release detailing the "First Quarter 2020 Financial Results" and includes unaudited consolidated financial statements as of March 31, 2020. A Form 6-K is used by foreign private issuers to report material information not required to be reported in their home country or filed on a Form 20-F. Since this filing contains the primary announcement of quarterly financial results (the press release) and the associated financial statements, it most closely aligns with the function of an Earnings Release (ER) or an Interim/Quarterly Report (IR). However, the SEC filing type itself (6-K) is a general reporting mechanism. Given the content is the full press release announcing quarterly results and financial highlights, the most appropriate classification among the provided options is Earnings Release (ER), as it serves the function of the initial announcement of periodical financial results. It is not the comprehensive Annual Report (10-K) or a standalone Audit Report (AR). It is also not merely an announcement of a report (RPA), as it contains the substance of the earnings release itself. Q1 2020
2020-05-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.